Here, read 5 case reports of patients with preexisting psychotic disorders seen on the inpatient psychiatry unit of an inner-city community hospital who decompensated for various reasons relating to the COVID-19 pandemic.
A wide range of psychological outcomes have been observed during the COVID-19 outbreak. Patients often experience the fear of getting sick or dying and feel helpless or stereotyped by others. Read this case report to find out more.
This study explored the sociodemographic and clinical details of patients of an outpatient psychiatric clinic to shed light on the impact of the COVID-19 pandemic and the needs of psychiatric patients during lockdown in South India.
Could increased social cohesion through shared experience mitigate the impact of pandemics on suicide rates? Here, the authors explore the impact of the 1918–1920 influenza pandemic on suicide rates and discuss their findings in the context of COVID-19.
This study focused on the first feelings, attitudes, and planned reactions of psychiatric workers in Hungary to the news of COVID-19 and examined differences between psychiatrists/psychologists and nurses/other professionals regarding these attitudes.
The pandemic has clearly placed a tremendous strain on health care workers, but how has it affected their ability to function in their daily lives and the likelihood of burnout? This large survey from a New York hospital provides some answers.
The COVID-19 pandemic has affected the daily life of millions worldwide, with still unclear effects on mental health. This study examined patterns in pediatric psychiatric visits to hospital emergency departments in Italy during the pandemic lockdown.
Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit
To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be particularly useful in patients with liver disease,” deserves comment.1
First, Andrade failed to recall that the first pivotal trial of baclofen, ALPADIR (NCT01738282; 320 patients, as with Bacloville), was negative (see Braillon et al2).
Second, Dr Andrade should have warned readers that Bacloville’s results are most questionable, lacking robustness. Although he cited us,3 he overlooked the evidence we provided indicating that the Bacloville article4 was published without acknowledging major changes to the initial protocol, affecting the primary outcome. Coincidentally (although as skeptics, we do not believe in coincidence), the initial statistical team was changed when data were sold to the French pharmaceutical company applying for the marketing authorization in France. As Ronald H. Coase warned, “If you torture the data long enough, it will confess.”
MY ACCOUNT